Biocad biotech company continues to increase the number of clinical trials of drugs for the treatment of oncological, autoimmune and orphan diseases. Since 2020,...
Investments in the production of Russian substances for medicines for 10 plants (to be launched starting from 2023) may amount to 50 billion rubles,...
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
